ClinicalTrials.gg
TerminatedNCT04815083Updated Sep 3, 2025Results posted

Fluorescence Imaging of Carcinoma During Breast Conserving Surgery

A Phase 3 interventional study of Aminolevulinic Acid Hydrochloride and Eagle V1.2 Imaging System in Breast Neoplasm Female and Breast Cancer, sponsored by SBI ALApharma Canada, Inc.. Terminated at 7 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-03.

Sponsored by SBI ALApharma Canada, Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
Study terminated due to closure of Sponsor business

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Breast conserving surgery (BCS) is performed on patients with breast cancer to resect and completely remove the cancer while conserving as much of the surrounding healthy tissue as possible. Current methods do not allow surgeons to determine the completeness of surgical resection in real-time. This often results in the need for a second surgical procedure, or in some cases more than two surgical procedures in order to have confidence that all cancer has been removed.

This Phase 3 study will evaluate the safety and efficacy of the fluorescent imaging agent PD G 506 A for the real-time visualization of cancer during standard of care breast conserving surgery. PD G 506 A is an investigational drug which is converted in the body into a fluorescent molecule that accumulates in cancer cells. Patients receiving PD G 506 A will undergo standard of care breast conserving surgery followed by fluorescence imaging and removal of any potentially cancerous tissue left behind in the surgical cavity.

Read the detailed description

Re-operations due to positive margins following breast conserving surgery (BCS) increase poor cosmesis, complications, discomfort, stress, adjuvant delay, medical costs and risk of local recurrence. Reducing positive margin rates can be achieved through optimizing surgical procedures. This study evaluates a new method for surgeons to visualize carcinoma in real-time, both in the surgical cavity and on the margins of excised specimen(s) during the index BCS procedure.

The active ingredient of PD G 506A is aminolevulinic acid hydrochloride (ALA HCl). ALA HCl is a prodrug that is metabolized intracellularly to form the fluorescent molecule protoporphyrin IX (PpIX). The exogenous application of ALA HCl leads to a highly selective accumulation of PpIX in malignant tissues.

This Phase 3, 2-part, single-blind [pathologist(s)-blinded] randomized placebo-controlled trial study is designed to evaluate the efficacy and safety of PD G 506 A to aid in the visualization of carcinoma during BCS. The Eagle V1.2 Imaging System will be used in this trial to visualize PpIX fluorescence.

Part A is an open-label training phase of the study to optimize workflow and Part B of the study is randomized and single-blind and will serve as the pivotal portion of the study.

02

Conditions studied

  • Breast Neoplasm Female
  • Breast Cancer

Browse trials for

Keywords

  • Breast conserving surgery
  • Fluorescence Imaging
  • Intraoperative margin assessment
03

In context

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's enrollment of 57 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

This is the only study on the registry with SBI ALApharma Canada, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female, 18 years or older
  2. or cytologically confirmed primary breast cancer (includes invasive lobular carcinoma, invasive ductal carcinoma, inflammatory breast cancer, papillary breast cancer, adenoid cystic carcinoma of the breast, mucinous breast cancer, metaplastic breast cancer, cribriform carcinoma and ductal carcinoma in situ, alone or in combination with invasive disease)
  3. Scheduled for a lumpectomy (including bilateral lumpectomy) of a breast (eligibility for breast conserving surgery/partial mastectomy based on clinical staging using TNM staging system (AJCC Cancer Staging Manual: Breast Cancer, 8th Edition70).
  4. Patient must have normal organ and bone marrow function and be appropriate surgical candidate per site standard of care
  5. Women of must agree to use adequate (hormonal or barrier method of birth control, abstinence) starting the day entering the study, and for the duration of the study period (until the Week 2 visit)

Exclusion criteria

Exclusion Criteria:

  1. Currently on (neo) therapy to treat another cancer
  2. Receiving or intended to receive neoadjuvant therapy to treat the primary breast cancer (including chemotherapy, endocrine therapy and radiotherapy)
  3. Stage 4 cancer, inclusive of disease
  4. Non-invasive diseases of the breast (includes lobular carcinoma in situ, phyllodes and Paget's disease of the breast)
  5. Patients who have had the following procedures performed on the involved breast:

    1. Surgery for a benign lesion(s) within 1 year of the BCS date
    2. Breast implants inserted within 1 year of the BCS date
    3. Breast reduction, surgery for malignant disease or mastectomy (at any time prior to the BCS date)
    4. Surgery for a benign lesion(s) or insertion of implants >1 year prior to the BCS date and who have signs of ongoing inflammation, active tissue healing and/or extensive scarring
    5. Radiation at any time prior to the BCS date and who have signs of ongoing inflammation, active tissue healing and/or extensive scarring
  6. Patients for whom intraoperative frozen section analysis is planned
  7. Patients who have not recovered from adverse events due an pharmaceutical or diagnostic agents administered more than 30 days prior to their scheduled surgical procedure
  8. History of to ALA HCl or porphyrins
  9. Known or documented personal or family history of porphyria
  10. Patient has a recording of any parameter as defined below:

    1. : Above
    2. (SGOT): > 2.5 X institutional upper limit of normal
    3. Alanine aminotransferase ( (SGPT): > 2.5 X institutional upper limit of normal
  11. Patient has serum creatinine >1.5 times institutional upper limit of normal, OR calculated > 60 mL/min/1.73 m² for patients with creatinine levels above institutional normal.
  12. Uncontrolled concurrent illness, that in the opinion of the Investigator would prevent the patient from participation in the study, including but not limited to:

    1. Ongoing or active infection;
    2. Cardiovascular disease (e.g. symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia).
  13. Patients who have the following collagen vascular diseases:

    1. Lupus
    2. Scleroderma
  14. Use of an investigational drug within 30 days of their scheduled surgical procedure
  15. Simultaneous use of other potentially phototoxic substances (such as St. John's wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones and tetracyclines), and topical preparations containing ALA for 24 hours during the perioperative period.
  16. Social or medical situations including uncontrolled psychiatric illnesses that would in the opinion of the Investigator limit compliance with study requirements (e.g. ability to travel for follow-up)
  17. Patients who are pregnant or become pregnant (it is unknown if ALA HCl is teratogenic or has abortifacient effects)
  18. Patients who are breast feeding (there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ALA HCl, breastfeeding should be discontinued if the mother is treated with ALA HCl)
  19. Inability to consent
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
57 participants (actual)

Study arms

  • Placebo comparator
    Standard of Care Arm

    Patients in this arm will receive the placebo orally approximately 3 hrs prior to anesthesia followed by standard of care BCS. Fluorescence imaging will be performed on tissue specimens resected prior to completion of standard of care resection. Fluorescence-guided resection will not be performed in patients in this arm.

    Drug: Placebo

  • Experimental
    PD G 506 A + Fluorescence-Guided Resection Arm

    Patients in this arm will receive PD G 506 A orally approximately 3 hrs prior to anesthesia followed by standard of care BCS. Fluorescence imaging will be performed on tissue specimens resected prior to completion of standard of care resection. Fluorescence imaging performed after SoC BCS is complete will guide the resection of additional tissue.

    Drug: Aminolevulinic Acid Hydrochloride · Device: Eagle V1.2 Imaging System

Interventions

  • PD G 506 A for oral solution (aminolevulinic acid \[ALA\] hydrochloride \[HCl\] granules for oral solution) is administered as a single dose (20 mg/kg body weight) approximately 3 hours (min 2 hours, max 4 hours) prior to anesthesia.

    Also known as: PD G 506 A

  • DeviceEagle V1.2 Imaging System

    Fluorescence imaging camera and associated accessories used to view and capture fluorescence and white light images and videos of the surgical cavity and excised tissue specimens during the surgical procedure.

  • DrugPlacebo

    Oral placebo is administered as a single dose approximately 3 hours (min 2 hours, max 4 hours) prior to anesthesia.

06

What researchers measure

Primary outcomes

  1. Positive Margin Conversion Rate

    Percentage of patients with negative-margins following fluorescence-guided resection (FGR) among patients all patients imaged

    Time frame: 2 weeks

  2. Diagnostic Performance (Specificity)

    Patient-level specificity to identify residual carcinoma

    Time frame: 2 weeks

  3. Diagnostic Performance (Sensitivity)

    Patient-level sensitivity to identify residual carcinoma

    Time frame: 2 weeks

Secondary outcomes

  1. Orientation-level Diagnostic Performance

    Orientation-level diagnostic performance of PD G 506 A-induced fluorescence to determine the presence or absence of cancer in the surgical cavity as compared to margin histopathology.

    Time frame: 2 weeks

  2. Positive Margin Conversion Rate Among All Patients

    Percentage of patients with at least one histopathology-positive margin following SoC who then have ALL histopathology-negative margins following FGR, among all patients imaged.

    Time frame: 2 weeks

  3. Patient-level Diagnostic Performance

    Patient-level sensitivity, specificity, NPV, PPV of PD G 506 A-induced fluorescence to determine the presence or absence of residual cancer.

    Time frame: 2 weeks

  4. Patient-level Diagnostic Performance of PD G 506 A to Detect Residual Cancer at the End of FGR With Modified Patient-level Definitions

    Patient-level sensitivity, specificity, PPV and NPV to determine the presence or absence of residual cancer in the surgical cavity at the end of FGR (using modified patient-level definitions).

    Time frame: 2 weeks

  5. Patient-level Diagnostic Performance of PD G 506 A to Detect Cancer After SoC BCS

    Patient-level sensitivity, specificity, PPV and NPV to determine the presence or absence of cancer in the surgical cavity after SoC BCS.

    Time frame: 2 weeks

  6. Patient-level Diagnostic Performance of PD G 506 A to Detect Cancer After SoC With Modified Patient-level Definitions

    Patient-level sensitivity, specificity, PPV and NPV to determine the presence or absence of cancer in the surgical cavity after SoC (using modified patient-level definitions).

    Time frame: 2 weeks

  7. Patient-level False Negative Rate of at the End of FGR

    Percentage of patients assessed as residual tumor negative at the end of FGR who had positive final margins on histopathology.

    Time frame: 2 weeks

  8. Patient-level False Positive Rate

    Percentage of patients in whom SOC final margins were carcinoma negative and all FL-driven shave specimens are carcinoma-negative.

    Time frame: 2 weeks

  9. Patients With Carcinoma-negative Margins After SoC Found to Have Residual Tumor Following SoC That Was Identified With FL Imaging

    Percentage of patients with histopathology-negative margins at the end of SoC who have at least one orientation that was both FL-positive and histopathology-positive among (1) patients with histopathology negative final margins after SOC and (2) all patients imaged.

    Time frame: 2 weeks

  10. Patient-level True Negative Rate at the End of SoC

    Percentage of patients with no fluorescence identified at the end of SoC in whom all final margins after SoC are histopathologically confirmed to be negative for carcinoma.

    Time frame: 2 weeks

  11. Patient-level Diagnostic Performance to Identify in Vivo Residual Carcinoma After FGR

    Patient-level in vivo diagnostic performance of PD G 506 A-induced fluorescence to determine the presence or absence of residual cancer in the surgical cavity at the end of FGR as compared to the final margin histopathology.

    Time frame: 2 weeks

  12. Orientation Discordant Fluorescence Status

    Percentage of orientations where in vivo and ex vivo fluorescence assessments are discordant.

    Time frame: 2 weeks

  13. Patient-level Re-operation Rate

    Percentage of patients receiving a 2nd surgery on the ipsilateral breast within 1 year of index BCS to remove suspected residual disease.

    Time frame: 1 year

  14. Patient-level Early Re-operation Rate

    Percentage of patients receiving an early 2nd surgery (planned or actual) on the ipsilateral breast related to positive final margins.

    Time frame: 3 - 6 months

  15. Amount of Tissue Removed With FGR Beyond SoC

    Weight (mg) of all tissue removed based on SoC and/of FGR.

    Time frame: 3 - 6 months

  16. Patient Satisfaction With Breast

    Patient satisfaction with the cosmetic outcome of breast conserving surgery performed based on SoC in combination with PD G 506 A and the Eagle V1.2 Imaging System.

    Time frame: 2 weeks, 3-, 6- and 12-months

07

Results

Posted Sep 3, 2025
Limitations and caveats
Study was terminated early prior to meeting expected enrolment for Part A. No formal data analysis was performed.

Participant flow

Participants were recruited between 04/27/2021 and 08/30//2025. Patients were recruited by their surgeon at surgical clinic visits. Participants were recruited at each of the 7 study sites.

Participant flow — Overall Study
MilestonePD G 506 A + Fluorescence-Guided Resection Arm
Started57
Pd g 506 a + fluorescence-guided resection arm50
Completed50
Not completed7
Withdrew: Physician decision1
Withdrew: Study pause2
Withdrew: Screening failure4

Outcome measures

PrimaryPositive Margin Conversion Rate

Percentage of patients with negative-margins following fluorescence-guided resection (FGR) among patients all patients imaged

Time frame:
2 weeks

No measurements were reported for this outcome.

PrimaryDiagnostic Performance (Specificity)

Patient-level specificity to identify residual carcinoma

Time frame:
2 weeks

No measurements were reported for this outcome.

PrimaryDiagnostic Performance (Sensitivity)

Patient-level sensitivity to identify residual carcinoma

Time frame:
2 weeks

No measurements were reported for this outcome.

SecondaryOrientation-level Diagnostic Performance

Orientation-level diagnostic performance of PD G 506 A-induced fluorescence to determine the presence or absence of cancer in the surgical cavity as compared to margin histopathology.

Time frame:
2 weeks

No measurements were reported for this outcome.

SecondaryPositive Margin Conversion Rate Among All Patients

Percentage of patients with at least one histopathology-positive margin following SoC who then have ALL histopathology-negative margins following FGR, among all patients imaged.

Time frame:
2 weeks

No measurements were reported for this outcome.

SecondaryPatient-level Diagnostic Performance

Patient-level sensitivity, specificity, NPV, PPV of PD G 506 A-induced fluorescence to determine the presence or absence of residual cancer.

Time frame:
2 weeks

No measurements were reported for this outcome.

SecondaryPatient-level Diagnostic Performance of PD G 506 A to Detect Residual Cancer at the End of FGR With Modified Patient-level Definitions

Patient-level sensitivity, specificity, PPV and NPV to determine the presence or absence of residual cancer in the surgical cavity at the end of FGR (using modified patient-level definitions).

Time frame:
2 weeks

No measurements were reported for this outcome.

SecondaryPatient-level Diagnostic Performance of PD G 506 A to Detect Cancer After SoC BCS

Patient-level sensitivity, specificity, PPV and NPV to determine the presence or absence of cancer in the surgical cavity after SoC BCS.

Time frame:
2 weeks

No measurements were reported for this outcome.

SecondaryPatient-level Diagnostic Performance of PD G 506 A to Detect Cancer After SoC With Modified Patient-level Definitions

Patient-level sensitivity, specificity, PPV and NPV to determine the presence or absence of cancer in the surgical cavity after SoC (using modified patient-level definitions).

Time frame:
2 weeks

No measurements were reported for this outcome.

SecondaryPatient-level False Negative Rate of at the End of FGR

Percentage of patients assessed as residual tumor negative at the end of FGR who had positive final margins on histopathology.

Time frame:
2 weeks

No measurements were reported for this outcome.

SecondaryPatient-level False Positive Rate

Percentage of patients in whom SOC final margins were carcinoma negative and all FL-driven shave specimens are carcinoma-negative.

Time frame:
2 weeks

No measurements were reported for this outcome.

SecondaryPatients With Carcinoma-negative Margins After SoC Found to Have Residual Tumor Following SoC That Was Identified With FL Imaging

Percentage of patients with histopathology-negative margins at the end of SoC who have at least one orientation that was both FL-positive and histopathology-positive among (1) patients with histopathology negative final margins after SOC and (2) all patients imaged.

Time frame:
2 weeks

No measurements were reported for this outcome.

SecondaryPatient-level True Negative Rate at the End of SoC

Percentage of patients with no fluorescence identified at the end of SoC in whom all final margins after SoC are histopathologically confirmed to be negative for carcinoma.

Time frame:
2 weeks

No measurements were reported for this outcome.

SecondaryPatient-level Diagnostic Performance to Identify in Vivo Residual Carcinoma After FGR

Patient-level in vivo diagnostic performance of PD G 506 A-induced fluorescence to determine the presence or absence of residual cancer in the surgical cavity at the end of FGR as compared to the final margin histopathology.

Time frame:
2 weeks

No measurements were reported for this outcome.

SecondaryOrientation Discordant Fluorescence Status

Percentage of orientations where in vivo and ex vivo fluorescence assessments are discordant.

Time frame:
2 weeks

No measurements were reported for this outcome.

SecondaryPatient-level Re-operation Rate

Percentage of patients receiving a 2nd surgery on the ipsilateral breast within 1 year of index BCS to remove suspected residual disease.

Time frame:
1 year

No measurements were reported for this outcome.

SecondaryPatient-level Early Re-operation Rate

Percentage of patients receiving an early 2nd surgery (planned or actual) on the ipsilateral breast related to positive final margins.

Time frame:
3 - 6 months

No measurements were reported for this outcome.

SecondaryAmount of Tissue Removed With FGR Beyond SoC

Weight (mg) of all tissue removed based on SoC and/of FGR.

Time frame:
3 - 6 months

No measurements were reported for this outcome.

SecondaryPatient Satisfaction With Breast

Patient satisfaction with the cosmetic outcome of breast conserving surgery performed based on SoC in combination with PD G 506 A and the Eagle V1.2 Imaging System.

Time frame:
2 weeks, 3-, 6- and 12-months

No measurements were reported for this outcome.

Adverse events

Collected over All adverse events were followed from the time of consent to through to the Week 2 visit (~14 days after surgery). If a serious or non-serious adverse event (AE) was recorded at the Week 2 visit, the participant was assessed for an additional 7 days for non-serious adverse events or for at least an additional 30 calendar days for serious adverse events following the Week 2 visit. Any serious adverse events were followed until resolution or stabilization.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PD G 506 A + Fluorescence-Guided Resection Arm (Part A)0/50 (0%)1/50 (2%)16/50 (32%)
Most frequent serious events
Most frequent serious events
EventPD G 506 A + Fluorescence-Guided Resection Arm (Part A)
HypotensionVascular disorders1/50
Most frequent other events
Most frequent other events
EventPD G 506 A + Fluorescence-Guided Resection Arm (Part A)
Procedural painInjury, poisoning and procedural complications8/50
NauseaGastrointestinal disorders6/50
Photosensitivity reactionSkin and subcutaneous tissue disorders4/50
Skin burning sensationSkin and subcutaneous tissue disorders3/50

Baseline characteristics

The aim of Part A of the study is to provide training to the participating sites on the study procedures, and to determine the final number of subjects required for analysis of the endpoints in Part B of the study. The study was terminated early after the completion of Part A and before the start of Part B.

Age, Categorical
Age, Categorical(Participants)PD G 506 A + Fluorescence-Guided Resection (Part A)
<=18 years0
Between 18 and 65 years35
>=65 years22
Sex: Female, Male
Sex: Female, Male(Participants)PD G 506 A + Fluorescence-Guided Resection (Part A)
Female57
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PD G 506 A + Fluorescence-Guided Resection (Part A)
Hispanic or Latino13
Not Hispanic or Latino43
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PD G 506 A + Fluorescence-Guided Resection (Part A)
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American9
White39
More than one race0
Unknown or Not Reported6
Region of Enrollment
Region of Enrollment(participants)PD G 506 A + Fluorescence-Guided Resection (Part A)
United States57
Diagnosis
Diagnosis(Participants)PD G 506 A + Fluorescence-Guided Resection (Part A)
Invasive carcinoma (± in situ carcinoma)39
In situ carcinoma13
Other (± in situ carcinoma)4
Not Reported1
08

Study locations

7 sites
  • Stamford Hospital
    Stamford, Connecticut 06902, United States
  • BayCare Morton Plant Hospital
    Clearwater, Florida 33756, United States
  • University of Miami Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Orlando Health, Inc.
    Orlando, Florida 32806, United States
  • BayCare St. Joseph's Hospital
    Tampa, Florida 33607, United States
  • Montefiore Medical Center
    The Bronx, New York 10467, United States
  • Aurora St. Luke's Medical Centre
    Milwaukee, Wisconsin 53215, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Oct 2024, 41 months.

Results were first posted in Sep 2025, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2021
First posted
Mar 24, 2021
StartActual
Apr 27, 2021
Primary completionActual
Oct 22, 2024
CompletionActual
Dec 20, 2024
Results first posted
Sep 3, 2025
Last update
Sep 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04815083
Lead sponsor
SBI ALApharma Canada, Inc.
Responsible party
Sponsor
First posted
Mar 24, 2021
Start date
Apr 27, 2021
Primary completion
Oct 22, 2024
Completion
Dec 20, 2024
Results posted
Sep 3, 2025
Last update
Sep 3, 2025

Study contacts

Ralph DaCosta, PhD
study director · SBI ALApharma Canada

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aminolevulinic Acid

Start the discussion